Tokai went public in September 2014. The company’s lead drug candidate, galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate for the treatment of prostate cancer.
Nearly $50 million in federal grants has helped advance its research and development of an Ebola vaccine.
U.S. Patent & Trademark Office (PTO) Issues Patent for Harpoon’s Minimally Invasive Mitral Valve Repair Device
Data storage is one of the most popular applications of cloud computing.
UM Ventures is organized to move research outcomes into products and services, tools and diagnostics that will benefit society.
Sign up to receive current new technology announcements and other UM Ventures news.
UM Ventures is a joint initiative of the University of Maryland, Baltimore and University of Maryland, College Park to commercialize technologies and expand industry collaboration.